Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung
New data for AMG 510 at ESMO show the drug is more active in lung than colorectal cancer, as was reported at ASCO, but Amgen's Greg Friberg notes that Phase I monotherapy and planned combination studies may shed more light on KRAS biology and efficacy in different tumor types.
You may also be interested in...
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
Relatively upbeat during the company’s Q1 call based on Amgen’s product mix, executives expect the biggest coronavirus-related sales impacts in Q2 with stabilization and growth in the second half.
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.